Novelix Pharmaceuticals Ltd

📈 Novelix Pharmaceuticals Q3 FY2026: Revenue Soars to ₹4840.27 Lakhs

• Total income for Q3 FY2026: ₹4,840.27 lakhs (vs. ₹530.09 lakhs in Q3 FY2025)

• Net profit after tax for Q3 FY2026: ₹100.44 lakhs (vs. ₹14.79 lakhs in Q3 FY2025)

• 9-month total income: ₹10,714.52 lakhs (vs. loss of ₹7.65 lakhs in prior year period)

• 9-month net profit: ₹164.46 lakhs (vs. loss of ₹7.65 lakhs in prior year period)

• Earnings per share (EPS) for continuing operations: ₹0.58 (basic) and ₹0.85 (diluted) for the quarter